Trial
NCT03580694
Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Regeneron Pharmaceuticals
Collaborators
—
Condition
Carcinoma, Non-Small-Cell Lung
Intervention
REGN4659
Why stopped
Program reprioritization
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-13